WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 6'3801 Infant (under 12 months) mortality rate: 202
GDP / capita (US$): 10'9871 Child (under 5 years) mortality rate: 212

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 109  109  109  109  109  108  108  101 
Births
Surviving infants
Pop. less than 5 years 11  13  15 
Pop. less than 15 years 28  29  29  29  30  34  41  44 
Female 15-49 years 29  29  29  29  29  28  25  23 

Number of reported case

(Click for retrospective incidence data for Saint Vincent and the Grenadines)
Diphtheria
Japanese encephalitis
Measles 257 
Mumps
Pertussis
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Saint Vincent and the Grenadines)
Vaccine year result method % card seen                                                
BCG          97  100  91  80  99*  100  100 
DTP1          94  94  94  99*  99*  91 
DTP3          96  96  100  99*  99*  100  98  26 
HepB_BD          20  60  70  100 
HepB3          96  96  100  99*  99* 
Hib3          97  96  99*  99*  99* 
JapEnc         
MCV          94  99*  100  99*  99*  96  96 
MCV2          92  99*  89  94  94 
PCV1         
PCV3         
Pol3          96  96  100  99*  99*  100  92  26 
Rota1         
Rota_last         
Rubella1          94  99*  100  99*  99* 
TT2plus          11 
PAB         
VAD1         
YFV          10  30 
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Saint Vincent and the Grenadines)
BCG 97  99  90  80  87  99  99 
DTP1 98  98  99  99  99  99  98  51 
DTP3 96  96  99  99  99  98  98  26 
HepB3 96  96  99  99  99 
Hib3 97  96  99  99  99 
MCV 94  97  99  99  99  96  96 
PCV3
Pol3 96  96  99  99  99  99  92  26 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 89
From 80 to 89% 0
From 50 to 79% 11
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth-12 months; Yes
DT 4-5 years; Yes
DTwP 18 months; Yes
DTwPHibHep 2, 4, 6 months; Yes
HIB 2, 4, 6 months; children who started vaccination overseas
HepB 1st contact; +1, +4-6 months; Yes at birth for hepatitis b exposed babies and adult at risk
IPV 2, 4, 6, 18 months; 4-5 years; Yes HIV+
MMR 1, 4-5 years; Yes
OPV 2, 4, 6, 18 months; 4-5 years; Yes
Td >10 years; Yes
YF Yes travellers

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR No  No  No  Yes  Yes  Yes   
What years does the MYP cover? number       2009-2011  2009-2011  2'007  2007-08 
Nº of districts with microplans that include activities to raise immunization coverage number 17 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR No  No  No         

System performance

Total number of districts in country number
Nº districts with DTP3 coverage >=80% number  
% of districts with DTP3 coverage >=80% From 0 to 100% 89  100  100  100  89  100   
Nº districts with measles (MCV1) coverage >=95% number    
% of districts with MCV1 coverage >=95% From 0 to 100% 56  78  56  89  89     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No  No  No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100  100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.